Towards Healthcare
Intravenous Immunoglobulin Market to Lead USD 40.78 Bn by 2034

Intravenous Immunoglobulin Market

Market insights predict, the intravenous immunoglobulin industry is expected to grow from USD 17.12 billion in 2024 to USD 40.78 billion by 2034, driven by a CAGR of 9.14%. The rising prevalence of immunological disorders and the increasing awareness of blood donations drive the global market. North America dominated the global market due to a robust healthcare infrastructure and favorable regulatory support.

  • Insight Code: 6177
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

FAQ's

The intravenous immunoglobulin market in 2025 is valued at USD 18.68 billion and is projected to climb to USD 40.78 billion by 2034, with a CAGR of 9.14% over the forecast period.

North America is leading the intravenous immunoglobulin market share 42% due to the availability of a robust healthcare infrastructure, increasing blood donations, and favorable regulatory support.

The intravenous immunoglobulin market includes six segments: by indication, by concentration, by formulation, by end-user, by distribution channel, and by region.

Some key players include Takeda Pharmaceuticals, ADMA Biologics, and SK Plasma Co., Ltd.

IVIG success rates range from 60% to 80% based on the type of disease, individual response, and the specific IVIG brand.

National Institute of Health, Food and Drug Administration, Canadian Blood Services, National Medical Products Administration, clinicaltrials.gov